ArticleFrontiers in oncology2026
The impact of early integrated palliative care on symptom burden and quality of life in patients with advanced breast cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with advanced breast cancer endure a high symptom burden and impaired quality of life. This study evaluated the impact of Early Integrated Palliative Care (EIPC) on these outcomes.
methodsA retrospective cohort study analyzed patients with advanced breast cancer treated between November 2018 and December 2021. Patients were categorized into an EIPC group or a usual care group based on the care model received. Symptom burden (SDS) and sleep quality (PSQI) were assessed at baseline, 6, 12, 18, and 24 weeks. Quality of life (FACT-B), hope (HHI), and anxiety/depression (HADS) were evaluated at baseline and 24 weeks. End-of-life chemotherapy rates were recorded.
resultsOf 200 included patients, 88 received EIPC, and 112 received usual care. The EIPC group demonstrated significantly lower SDS scores from week 6 onward (24 weeks: 27.57 vs. 29.71, P = 0.002) and lower PSQI scores (24 weeks: 7.21 vs. 8.19, P = 0.002). At 24 weeks, the EIPC group had significantly higher FACT-B scores in physical, social/family, emotional, and functional well-being domains (all P<0.05), higher HHI scores (positive attitude: 13.06 vs. 12.44, P = 0.004), and lower HADS depression (6.45 vs. 7.36, P = 0.002) and anxiety scores (6.23 vs. 7.18, P = 0.001). The rate of chemotherapy in the last 6 weeks of life was significantly lower in the EIPC group (20.45% vs. 40.18%, P = 0.003).
conclusionEIPC alleviates symptom burden, improves quality of life, psychological well-being, and sleep, and promotes more goal-concordant end-of-life care in patients with advanced breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.